Chemocentryx, Inc. (CCXI) Files Form 4 Insider Buying : Thomas A. Edwards Buys 25,000 Shares

Chemocentryx, Inc. (CCXI): Thomas A. Edwards , director of Chemocentryx, Inc. purchased 25,000 shares on May 16, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.05 per share for a total value of $101,212.50 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Geoffrey M. Parker (director) purchased 40,000 shares at $4.03 per share price.On Jan 22, 2016, Susan M Kanaya (SVP, Finance, CFO and Sec.) sold 25,764 shares at $4.04 per share price.Also, On May 26, 2015, Ira Klein (director) sold 10,811 shares at $7.45 per share price.On May 26, 2015, James L Tyree (director) sold 12,703 shares at $7.45 per share price.

Shares of ChemoCentryx Inc (CCXI) ended Friday, May 13, 2016 session in red amid volatile trading. The shares closed down -0.16 points or -4.02% at $3.82 with 22,43,347 shares getting traded. Post opening the session at $3.98, the shares hit an intraday low of $3.7 and an intraday high of $4.13 and the price vacillated in this range throughout the day. The company has a market cap of $169 M and the number of outstanding shares has been calculated to be 4,42,90,506 shares. The 52-week high of ChemoCentryx Inc is $9.46 and the 52-week low is $1.9214.

ChemoCentryx Inc Money Flow Index Chart

ChemoCentryx Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer. It targets the chemoattractant system which is a network of molecules including chemokine ligands and their associated receptors as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The Company’s product portfolio includes CCX140 CCX872 CCX168 Vercirnon (Traficet-EN or CCX282) and CCX507.

Leave a Reply

ChemoCentryx Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on ChemoCentryx Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.